ImmunoCellular Therapeutics Ltd. is reviewing strategic options for its assets and business to enhance stockholder value.

The Los Angeles-based biotechnology is focused on developing immune-based therapies to treat cancer. Its clinical-stage programs include ICT-107, for treating newly diagnosed glioblastoma or brain cancer; ICT-121 to treat recurring glioblastoma; and ICT-140 for ovarian cancer.

ImmunoCellular previously reported a net loss of $13.9 million and no revenue for the nine months ended Sept. 30, 2017. ImmunoCellular had noted that it did not expect to have any revenue for full year 2017.

The company said there can be no guarantee that the review will result in a transaction.

Ladenburg Thalmann & Co. Inc. is acting as a strategic financial adviser to the company for the process.